Impact of Renal Denervation in Patients With Coronary Microvascular Dysfunction: Study Design and Rationale

NCT ID: NCT05994729

Last Updated: 2023-10-24

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 87 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-01
• Study Completion Date: 2026-12-31

Brief Summary

Long-standing hypertension may cause an impairment in microvascular coronary circulation which is involved in many different cardiac conditions. Renal denervation (RDN) has been successfully proven as a valuable and powerful therapeutic choice to consider for patients with resistant hypertension; moreover this procedure looks promising in other cardiac disease such as heart failure and atrial fibrillation, given its ability to downregulate sympathetic nervous system The aim of this study is to explore the effect of renal denervation and blood pressure control on coronary microvascular dysfunction.

This is a multicenter, prospective, non randomized, open-label, interventional study. Consecutive patients with resistant hypertension, non obstructive coronary artery disease and documented microvascular dysfunction will be enrolled. Patients will undergo renal denervation by Spyral Symplicity 3 and re-assessment of coronary microvascular function 12 months after the procedure. Primary endpoint will be the difference in average index of microcirculatory resistance value.

Detailed Description

The aim of this study is to evaluate the effect of radiofrequency RDN performed with Spyral Symplicity 3 on microvascular function in patients with ascertained hypertension related coronary microvascular dysfunction (hy-CMD) and/or hypertensive cardiomyopathy. Our hypothesis is that RDN could improve invasive parameters of microvascular function in patients with hy-CMD; these would mean that RDN would be able to at least partially revert the pathogenesis of hy-CMD.

The study design comprises an initial rule-in and enrollment phase, required to properly select the target population, followed by the actual study procedural phase.

Patients amenable to RDN will be hospitalized and enter the rule-in phase to check for eligibility.

Before performing the actual RDN, patients will be asked for the written informed consent to receive physiological evaluation.

Only patients that will be diagnosed with hy-CMD will eventually enter the actual study phase.

This phase will comprise repeated outpatients visits, according to a predetermined schedule, including a new hospitalization at 12 months to reassess coronary microvascular physiology.

Conditions

Coronary Microvascular Dysfunction; Resistant Hypertension; Hypertensive Heart Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Candidates to RDN with ascertained CMD

Patients that are candidates to receive RDN for resistant/difficult to control hypertension, who also have documented coronary microvascular dysfunction

Group Type: EXPERIMENTAL

Invasive Physiological Assessment of Coronary Circulation

Intervention Type: DIAGNOSTIC_TEST

After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.

Interventions

Invasive Physiological Assessment of Coronary Circulation

After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

CFR; IMR; Tmn

Eligibility Criteria

Inclusion Criteria

• Non obstructive stable coronary artery disease (CAD) on invasive coronary angiography (defined as the absence of either >50% angiographic stenosis or any flow limiting lesion on functional evaluation)
• Suspected diagnosis of difficult to control/ resistant hypertension for which renal denervation by radiofrequency ablation with Spyral Symplicity 3 could be considered.

• Having coronary microvascular dysfunction documented by invasive functional assessment (IMR>25 and or CFR < 2)

Exclusion Criteria

• Initiation of either nitrates, beta-blocker or calcium channel blocker less than 30 days before the end of the rule-in phase
• Physiological assessment performed during first medical contact documenting preserved coronary microvascular function
• Physiological assessment performed at the "first contact" hospitalization followed by modification of medical therapy during the rule-in phase, before RDN
• Acceptable blood pressure control after medical treatment optimization
• Identification of secondary causes of hypertension
• Renal artery anatomy not suitable for RDN
• Ejection fraction below 30%
• Life expectancy below 1 year
• Indication to cardiac surgery
• Adenosine allergy
• Pregnancy
• Large necrotic area documented by either MRI, SPECT or combination of ECG signs + Echocardiographic images.
• Hemodynamic instability
• Refuse to sign informed consent
• Age below 18 or above 80

• Refuse to sign informed consent
• Evidence of newly detected obstructive CAD on invasive coronary angiography performed 6 months after RDN

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aurelia Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fabrizio Tomai, MD, FACC, FESC

Role: PRINCIPAL_INVESTIGATOR

Aurelia Hospital

stefano migliaro, MD

Role: STUDY_CHAIR

Aurelia Hospital

Central Contacts

Fabrizio Tomai, MD, FACC, FESC

Role: CONTACT

fabriziotomai@gmail.com

0039 06 65975725

stefano migliaro, MD

Role: CONTACT

migliaro.stefano@gmail.com

0039 3453373825

Other Identifiers

AH Card. 08-23

Identifier Type: -

Identifier Source: org_study_id